Has Michael Young, MD received payments from drug or device companies?

Yes. Drug and device makers reported $53,283 in general payments to Michael Young, MD across 193 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Michael Young, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Michael Young, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Michael Young, MD

Cardiovascular Disease · Lebanon, NHNPI 1891938395

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (45.7%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Edwards Lifesciences at 50.5% of the total. 2025 is the largest year on record at $19,213, more than ten times the $76 reported in 2019. Among cardiovascular disease clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$53,283in general payments, 2019–2025

Across 193 payments — averaging $276.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Edwards Lifesciences$27K
Boston Scientific$13K
Medtronic$11K
Abbott$3K
Inari Medical, Inc.$100
Spectrawave, Inc$19
plus $14 from 1 others

$1,734,805in research payments, 2019–2025

Across 142 payments — averaging $12,217 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Edwards Lifesciences$1.4M
Boston Scientific$257K
Abbott$25K
EKOS Corporation$4K

What the payments were for

Consulting fees$24,35046%
Speaking & faculty fees$3,4386%
Travel & lodging$15,40429%
Food & beverage$10,09219%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Edwards Lifesciences	93	$26,898
Boston Scientific	23	$12,565
Medtronic	41	$10,673
Abbott	33	$3,013
Inari Medical, Inc.	1	$100
Spectrawave, Inc	1	$19
Angiodynamics, Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Edwards SAPIEN 3 Transcatheter Heart Valve$18,009
COREVALVE EVOLUT R$9,104
WATCHMAN Access System$5,313
EKOSONIC$3,956
EVOQUE$1,345
WATCHMAN FLX$750
AMPLATZER$548
SYMPLICITY G3$415
Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$413
MitraClip$286
PORTICO$276
SYNERGY$163
NAVITOR$150
CoreValve Evolut$147
SAPIEN 3 Ultra RESILIA$138
GENERAL VASCULAR INTERVENTION$132
FLOWTRIEVER CATHETER, S$100
CT THROMBECTOMY SYSTEM KIT$100

How this compares

$53,283 in reported general payments places this provider in the 95th percentile of 112 cardiovascular disease providers in New Hampshire.

See all cardiovascular disease providers in New Hampshire →

Medicare billing

Part B allowed, 2024

$196,485

Medicare patients

340

Services billed

866

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	12	$9,327
Metoprolol Succinate	28	$316

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Lebanon

Kevin KwakuLebanon$79K
Merle MyersonLebanon$15K
Ian GilchristLebanon$13K
Robert DangeloLebanon$10K
Rumman SyedLebanon$9K
Mohammadtokir MujtabaLebanon$8K
Lauren Gilstrap MilleyLebanon$5K
Fernando Contreras-ValdesLebanon$5K
David MinLebanon$3K
Monika BernasLebanon$3K

See the full list for New Hampshire →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →